References
- Loftus P. U.S. Drug spending climbs. Wall Street Journal. 14 April 2016. Available at: http://www.wsj.com/articles/u-s-drug-spending-climbs-1460606462 [Last accessed 8 December 2016]
- National health expenditures per capita. Kaiser Family Foundation. Updated 28 February 2014. Available at: http://kff.org/health-costs/slide/national-health-expenditures-per-capita/ [Last accessed 8 December 2016]
- NHE Fact Sheet. Baltimore: Centers for Medicare & Medicaid Services, updated 12 December 2016. Available at: https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/nationalhealthexpenddata/nhe-fact-sheet.html [Last accessed 8 December 2016]
- Observations on trends in prescription drug spending. Office of the Assistant Secretary for Planning and Evaluation, updated 8 March 2016. Available at: https://aspe.hhs.gov/sites/default/files/pdf/187586/Drugspending.pdf [Last accessed 8 December 2016]
- OECD. Health at a Glance 2015: OECD Indicators. Paris: OECD Publishing, 2015
- Lupkin S, Kaiser Health News. 5 reasons prescription drug prices are so high in the U.S. Money. 23 August 2016. Available at: http://time.com/money/4462919/prescription-drug-prices-too-high/ [Last accessed 8 December 2016]
- IMS health study: U.S. drug spending growth reaches 8.5 percent in 2015. QuintilesIMS Incorporated, updated 14 April 2016. Available at: https://www.imshealth.com/en/about-us/news/ims-health-study-us-drug-spending-growth-reaches-8.5-percent-in-2015 [Last accessed 8 December 2016]
- Addressing the myths about ICER and value assessment. Institute for Clinical and Economic Review. Available at: http://icer-review.org/wp-content/uploads/2016/08/icer_myths_facts.pdf [Last accessed 29 March 2017]
- ICER draft report on effectiveness, value, and pricing benchmarks for PCSK9 inhibitors for high cholesterol posted for public comment. Institute for Clinical and Economic Review, updated 8 September 2015. Available at: https://icer-review.org/announcements/pcsk9-draft-report-release/ [Last accessed 8 December 2016]
- Schulman KA, Balu S, Reed SD. Specialty pharmaceuticals for hyperlipidemia – impact on insurance premiums. N Engl J Med 2015;373:1591-3
- Herper M. Gilead’s $1,000 Pill Could Eradicate Hepatitis C, But Ethical And Financial Challenges Loom. Forbes, 19 December 2013. Available at: http://www.forbes.com/sites/matthewherper/2013/12/19/can-gileads-1000-pill-eradicate-hepatitis-c/#40afe9cc1417 [Last accessed 8 December 2016]
- 10 essential facts about Medicare and prescription drug spending. Kaiser Family Foundation, updated 7 July 2016. Available at: http://kff.org/infographic/10-essential-facts-about-medicare-and-prescription-drug-spending/ [Last accessed 8 December 2016]
- What’s California’s prescription for rising drug costs? CalMatters, updated 10 April 2016. Available at: https://calmatters.org/articles/californiatakes-measures-to-control-drug-spending-but-costs-soar/ [Last accessed 8 December 2016]
- Examining high prescription drug spending for people with employer sponsored health insurance. Peterson-Kaiser Health System Tracker, updated 27 October 2016. Available at: http://www.healthsystemtracker.org/insight/examining-high-prescription-drug-spending-for-people-with-employer-sponsored-health-insurance/ [Last accessed 8 December 2016]
- 2012 Novel New Drugs Summary. US Food and Drug Administration Center for Drug Evaluation and Research, updated January 2013. Available at: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM337830 [Last accessed 22 February 2017]
- 2013 Novel New Drugs Summary. US Food and Drug Administration Center for Drug Evaluation and Research, updated January 2014. Available at: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM381803 [Last accessed 22 February 2017]
- 2014 Novel New Drugs Summary. US Food and Drug Administration Center for Drug Evaluation and Research, [updated January 2015. Available at: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM430299 [Last accessed 22 February 2017]
- 2015 Novel New Drugs Summary. US Food and Drug Administration Center for Drug Evaluation and Research, updated January 2016. Available at: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM485053 [Last accessed 22 February 2017]
- Tice JA, Ollendorf DA, Cunningham C, et al. PCSK9 Inhibitors for Treatment of High Cholesterol: Effectiveness, Value, and Value Based Price Benchmarks Draft Report. Boston (MA): Institute for Clinical and Economic Review, 2015
- Vishwanath R, Hemphill LC. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy. J Clin Lipidol 2014;8:18-28
- Gilead Wins FDA Approval for Blockbuster Hepatitis C Pill. Bloomberg LP, updated 6 December 2013. Available at: http://www.bloomberg.com/news/articles/2013-12-06/gilead-wins-fda-approval-for-blockbuster-hepatitis-c-pill [Last accessed 8 December 2016]
- Fourth Quarter 2016. Gilead Sciences Inc., 2017. Available at: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-earnings [Last accessed 22 February 2017]
- Weinstein D. Analyst gives PCSK9 preview. Medical Marketing and Media. 25 March 2014. Available at: http://www.mmm-online.com/channel/analyst-gives-pcsk9-preview/article/339712/ [Last accessed 8 December 2016]
- Loftus P. FDA Approves AbbVie’s Hepatitis Treatment. Wall Street Journal. 19 December 2014. Available at: http://www.wsj.com/articles/fda-approves-abbvies-hepatitis-treatment-1419019392 [Last accessed 8 December 2016]
- AbbVie Reports Full-Year 2015 and Fourth-Quarter Financial Results. PR Newswire, updated 29 January 2016. Available at: http://www.prnewswire.com/news-releases/abbvie-reports-full-year-2015-and-fourth-quarter-financial-results-300212080.html [Last accessed 8 December 2016]
- PwC Health Research Institute. Medical Cost Trend: Behind the Numbers 2016. Pricewaterhouse Coopers LLP, 2015
- Financial Release. Abbvie, updated January 2017. Available at: http://investors.abbvie.com/phoenix.zhtml?c=251551&p=irol-newsArticle&ID =2240300 [Last accessed 22 February 2017]
- Gilead Sciences Announces Fourth Quarter and Full Year 2014 Financial Results. Foster City (CA): Gilead Sciences Inc., 2015. Available at: http://www.gilead.com/news/press-releases/2015/2/gilead-sciences-announces-fourth-quarter-and-full-year-2014-financial-results [Last accessed 8 December 2016]
- AbbVie Prices Hepatitis C Drug 12% Below Gilead Rival. Bloomberg LP, updated 19 December 2014. Available at: http://www.bloomberg.com/news/articles/2014-12-19/abbvie-wins-u-s-approval-to-sell-new-hep-c-competitor [Last accessed 8 December 2016]
- Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results. New York (NY): Bristol-Myers Squibb, 2017. Available at: http://s2.q4cdn.com/139948097/files/doc_financials/q4-2016/Q42016-Earnings-Release.pdf [Last accessed 22 February 2017]
- Bristol-Myers Hits 14-Year High as Cancer Drug’s Use Expands. Bloomberg LP, updated 4 March 2015. Available at: http://www.bloomberg.com/news/articles/2015-03-04/bristol-myers-wins-early-approval-to-use-opdivo-for-lung-cancer [Last accessed 8 December 2016]
- Demko P. Gilead Sciences gets go-ahead for Harvoni, its second high-priced hepatitis C drug. Modern Healthcare. 10 October 2014. Available at: http://www.modernhealthcare.com/article/20141010/NEWS/310109947 [Last accessed 8 December 2016]
- Q4 and Full Year 2016 Results. Sanofi, updated 20 February 2017. Available at: http://en.sanofi.com/investors/events/Results/2017-02-08_Results_FY_2016.aspx [Last accessed 22 February 2017]
- Ollendorf DA, Sandhu AT, Chapman R, et al. CardioMEMS HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto, Novartis AG) for Management of Congestive Heart Failure: Effectiveness, Value, and Value-Based Price Benchmarks. Boston, MA: Institute for Clinical and Economic Review, 2015
- Annual Report 2016. Basel, Switzerland: Novartis, 2017. Available at: https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2016-en.pdf [Last accessed 22 February 2017]
- FirstWord Lists – the biggest drug approvals of 2015. Doctor’s Guide Publishing Limited, 2015. Available at: http://www.firstwordpharma.com/node/1291101 [Last accessed 8 December 2016]
- Pfizer Reports Fourth-Quarter and Full-Year 2016 Results Provides 2017 Financial Guidance. New York, NY: Pfizer, 2017. Available at: http://www.pfizer.com/system/files/presentation/Q4_2016_PFE_Earnings_Press_Release_dwerfks.pdf [Last accessed 22 February 2017]
- Jago C. 2015 Drugs to Watch: Thomson Reuters Market Insight Report. Thomson Reuters, 2015
- Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results. New York, NY: Bristol-Myers Squibb, 2016. Available at: http://investor.bms.com/investors/news-and-events/press-releases/press-release-details/2016/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-2015-Financial-Results/default.aspx [Last accessed 8 December 2016]
- Yukhananov A, Berkrot B. FDA approves Vertex cystic fibrosis drug, shares jump. Reuters, 31 January 2012. Available at: http://www.reuters.com/article/us-fda-vertex-kalydeco-idUSTRE80U29N20120131 [Last accessed 8 December 2016]
- Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results. Boston, MA: Vertex Pharmaceuticals Incorporated, 2015. Available at: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=952025 [Last accessed 8 December 2016]
- Clarke T. FDA approves Johnson & Johnson diabetes drug, canagliflozin. Reuters. 29 March 2013. Available at: http://www.reuters.com/article/us-usa-johnsonandjohnson-diabetes-idUSBRE92S0EY20130329 [Last accessed 8 December 2016]
- Johnson & Johnson Reports 2016 Fourth-Quarter Results. New Brunswick, NJ: Johnson & Johnson, 2017. Available at: http://files.shareholder.com/downloads/JNJ/3725220598x0x924921/BCDFDBBF-7CC2-49FF-8ECF-3EC12FC88406/JNJ_News_2017_1_24_Financial_Releases.pdf [Last accessed 22 February 2017]
- Amgen Reports Fourth Quarter And Full Year 2016 Financial Results. Thousand Oaks, CA: Amgen, 2017. Available at: https://www.amgen.com/media/news-releases/2017/02/amgen-reports-fourth-quarter-and-full-year-2016-financial-results/ [Last accessed 22 February 2017]
- FDA approves Zykadia for late-stage lung cancer. Pharmafile, 2014. Available at: http://www.pharmafile.com/news/185456/fda-approves-zykadia-late-stage-lung-cancer [Last accessed 8 December 2016]
- Annual Report 2015. Basel, Switzerland: Novartis, 2016. Available at: https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2015-en.pdf [Last accessed 8 December 2016]
- Reuters. Long-awaited diet pill Contrave wins approval from the FDA for sale in the U.S. Daily Mail. 11 September 2014. Available at: http://www.dailymail.co.uk/femail/article-2751486/Long-awaited-diet-pill-gets-U-S-approval.html [Last accessed 8 December 2016]
- Mikkelsen O. Novo Nordisk to promote drug to treat obesity in United States. Reuters. 29 December 2014. Available at: http://www.reuters.com/article/novo-nordisk-obesity-fda-idUSL6N0UD0MB20141229 [Last accessed 8 December 2016]
- Financial report for the period 1 January 2016 to 30 September 2016. Novo Nordisk. Available at: http://www.novonordisk.com/content/dam/Denmark/HQ/investors/irmaterial/quarterly_financial_reports/2016/20161028_financial%20report_Q3%202016_UK.pdf [Last accessed 8 December 2016]
- Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014;106(5). pii:dju055.
- Browse the SEER Cancer Statistics Review 1975–2013. National Cancer Institute. Available at: https://seer.cancer.gov/csr/1975_2013/browse_csr.php?sectionSEL=4&pageSEL=sect_04_table.24.html [Last accessed 22 February 2017]
- Chia PL, Mitchell P, Dobrovic A, et al. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol 2014;6:423-32
- Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94
- Browse the SEER Cancer Statistics Review 1975–2013. National Cancer Institute. Available at: https://seer.cancer.gov/csr/1975_2013/browse_csr.php?sectionSEL=15&pageSEL=sect_15_table.27.html [Last accessed 22 February 2017]
- Financial Results for 2nd Q of FY2016 Data Book. Takeda Pharmaceutical Company Limited. Available at: https://www.takeda.com/investor-information/files/qr2016_q2_d_en.pdf [Last accessed 8 December 2016]
- Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2016. San Diego, CA: Orexigen, 2016. Available at: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=2219423 [Last accessed 8 December 2016]
- Overweight and Obesity Statistics. The National Institute of Diabetes and Digestive and Kidney Diseases, 2012. Available at: https://www.niddk.nih.gov/health-information/health-statistics/Pages/overweight-obesity-statistics.aspx [Last accessed 22 February 2017]
- Total Population by Child and Adult Populations. The Annie E. Casey Foundation, updated August 2016. Available at: http://datacenter.kidscount.org/data/tables/99-total-population-by-child-and-adult#detailed/1/any/false/573,869,36,868,867/39,40,41/416,417 [Last accessed 22 February 2017]
- Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50
- Cha M, Rifai B, Sarraf P. Pharmaceutical forecasting: throwing darts? Nat Rev Drug Discov 2013;12:737-8
- De Bondt WFM, Thaler RH. Do security analysts overreact? Am Econ Rev 1990;80:52-7
- Tversky A. Assessing uncertainty. J R Stat Soc Series B Stat Methodol 1974;36:148-59
- Barua S, Greenwald R, Grebely J, et al. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015;163:215-23
- HCV guidance: recommendations for testing, managing, and treating hepatitis C. American Association for the Study of Liver Diseases, updated October 2016. Available at: http://www.hcvguidelines.org/full-report-view [Last accessed 8 December 2016]
- United States District Court Western District of Washington at Seattle: Case No. C16-227-JCC Order granting plaintiffs’ motion for preliminary injunction. Updated 27 May 2016. Available at: http://freepdfhosting.com/f5e867945e.pdf [Last accessed 8 December 2016]
- Reimbursement restrictions have severely limited uptake of the PCSK9 inhibitors. Datamonitor Limited, updated 30 May 2016. Available at: http://www.datamonitorhealthcare.com/reimbursement-restrictions-have-severely-limited-uptake-of-the-pcsk9-inhibitors/ [Last accessed 8 December 2016]
- Sanofi, Amgen set to get U.K. access for drugs with discount. Bloomberg LP, updated 5 May 2016. Available at: https://www.bloomberg.com/news/articles/2016-05-05/sanofi-amgen-set-to-get-u-k-access-for-key-drugs-with-discount [Last accessed 8 December 2016]
- Express Scripts Medicare (PDP) 2016 formulary (list of covered drugs). Express Scripts Holding Company, updated 19 October 2016. Available at: https://www.express-scripts.com/art/medicare16/pdf/16pdp_formulary_choice.pdf [Last accessed 8 December 2016]
- Godman B, Malmström RE, Diogene E, et al. Dabigatran – a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Front Pharmacol 2014;5:109
- Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014;73:198-206
- 2016 Novel New Drugs Summary. US Food and Drug Administration Center for Drug Evaluation and Research, updated January 2017. Available at: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM536693 [Last accessed 4 April 2017]
- Johnson CY. A window into one of the most baffling things about drug prices. Washington Post. 18 March 2016. Available at: https://www.washingtonpost.com/news/wonk/wp/2016/03/18/a-window-into-one-of-the-most-baffling-things-about-drug-prices/?utm_term=.4d993c1ceadd [Last accessed 8 December 2016]